Education
About Us
Working with TipRanks
Follow Us
Biomerica Inc (BMRA)
NASDAQ:BMRA
BMRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.08 - $10.16
Previous CloseN/A
Volume74.49K
Average Volume (3M)1.63M
Market Cap
$7.94M
Enterprise Value$5.82M
Total Cash (Recent Filing)$3.06M
Total Debt (Recent Filing)$543.00K
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Oct 10, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding2,815,410
10 Day Avg. Volume744,784
30 Day Avg. Volume1,630,079
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue1.03
Enterprise Value/Gross Profit7.61
Enterprise Value/Ebitda-1.24
Forecast
1Y Price Target
$3.00Price Target Upside9.09% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering1
Biomerica News
BMRA FAQ
What was Biomerica Inc’s price range in the past 12 months?
Biomerica Inc lowest stock price was $2.08 and its highest was $10.16 in the past 12 months.
What is Biomerica Inc’s market cap?
Biomerica Inc’s market cap is $7.94M.
When is Biomerica Inc’s upcoming earnings report date?
Biomerica Inc’s upcoming earnings report date is Oct 10, 2025 which is in 33 days.
How were Biomerica Inc’s earnings last quarter?
Biomerica Inc released its earnings results on Aug 29, 2025. The company reported -$0.606 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.606.
Is Biomerica Inc overvalued?
According to Wall Street analysts Biomerica Inc’s price is currently Undervalued.
Does Biomerica Inc pay dividends?
Biomerica Inc does not currently pay dividends.
What is Biomerica Inc’s EPS estimate?
Biomerica Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biomerica Inc have?
Biomerica Inc has 2,815,410 shares outstanding.
What happened to Biomerica Inc’s price movement after its last earnings report?
Biomerica Inc reported an EPS of -$0.606 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.153%.
Which hedge fund is a major shareholder of Biomerica Inc?
Currently, no hedge funds are holding shares in BMRA
Company Description
Biomerica Inc
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
BMRA Stock 12 Month Forecast
Average Price Target
$3.00
▲(9.09% Upside)
Technical Analysis
Ownership Overview
77.92% Insiders
7.61% Mutual Funds
0.46% Other Institutional Investors
13.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---